An in-silico approach to predict and exploit synthetic lethality in cancer metabolism
Exploiting synthetic lethality is a promising approach for cancer therapy. Here, the authors present an approach to identifying such interactions by finding genetic minimal cut sets (gMCSs) that block cancer proliferation, and apply it to study the lethality of RRM1 inhibition in multiple myeloma.
Guardado en:
Autores principales: | Iñigo Apaolaza, Edurne San José-Eneriz, Luis Tobalina, Estíbaliz Miranda, Leire Garate, Xabier Agirre, Felipe Prósper, Francisco J. Planes |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ef8cc22898f64ca2b56b0ae347ed3a4f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence
por: Hubert Fleury, et al.
Publicado: (2019) -
Frequent and simultaneous epigenetic inactivation of TP53 pathway genes in acute lymphoblastic leukemia.
por: Amaia Vilas-Zornoza, et al.
Publicado: (2011) -
The tumor therapy landscape of synthetic lethality
por: Biyu Zhang, et al.
Publicado: (2021) -
RAD52: Paradigm of Synthetic Lethality and New Developments
por: Matthew J. Rossi, et al.
Publicado: (2021) -
Harnessing synthetic lethality to predict the response to cancer treatment
por: Joo Sang Lee, et al.
Publicado: (2018)